Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 4, 2013, Pages 1315-1320

  Wang, Jun ^a   Wu, Yibing ^a   Ma, Chunlong ^b   Fiorin, Giacomo ^c   Wang, Jizhou ^d   Pinto, Lawrence H ^b   Lamb, Robert A ^b   Klein, Michael L ^c   DeGrado, William F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Temple University   (United States)

^d Influmedix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; AMANTADINE; AMMONIA; ISOXAZOLE; OXADIAZOLE; OXADIAZOLE DERIVATIVE; PROTON; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; IC 50; INFLUENZA A; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT;

EID: 84872875683     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216526110     Document Type: Article

References (41)

1. De Clercq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5(12):1015-1025.
2. Cady SD, et al. (2010) Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463(7281):689-692.
3. Stouffer AL, et al. (2008) Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451(7178):596-599.
4. Wang J, et al. (2011) Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. J Am Chem Soc 133(35):13844-13847.
5. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4(11):3021-3024.
6. Grambas S, Hay AJ (1992) Maturation of influenza A virus hemagglutinin - Estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 190(1):11-18.
7. Shiraishi K, et al. (2003) High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188(1):57-61.
8. Abed Y, Goyette N, Boivin G (2005) Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 49(2):556-559.
9. Suzuki H, et al. (2003) Emergence of amantadine-resistant influenza A viruses: Epidemiological study. J Infect Chemother 9(3):195-200.
10. Furuse Y, Suzuki A, Oshitani H (2009) Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. Antimicrob Agents Chemother 53(10):4457-4463.
11. Krumbholz A, et al. (2009) High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol 90(Pt 4):900-908.
12. Deyde V, et al. (2009) Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respir Viruses 3(6):297-314.
13. Deyde VM, et al. (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196(2):249-257.
14. Simonsen L, et al. (2007) The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 24(8):1811-1820.
15. Schmidtke M, et al. (2006) Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 49(5):286-293.
16. Stouffer AL, et al. (2008) The interplay of functional tuning, drug resistance, and thermodynamic stability in the evolution of the M2 proton channel from the influenza A virus. Structure 16(7):1067-1076.
17. Balannik V, et al. (2010) Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel. Biochemistry 49(4):696-708.
18. Lagoja IM, De Clercq E (2008) Anti-influenza virus agents: Synthesis and mode of action. Med Res Rev 28(1):1-38.
19. Duque MD, et al. (2011) Inhibitors of the M2 channel of influenza A virus. Recent Advances in Pharmaceutical Sciences 35-64.
20. Severson WE, et al. (2008) High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J Biomol Screen 13(9):879-887.
21. Wang J, et al. (2011) Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. ACS Med Chem Lett 2(4):307-312.
22. Balannik V, et al. (2009) Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 48(50):11872-11882.
23. Wang J, et al. (2011) Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J Am Chem Soc 133(32):12834-12841.
24. Pielak RM, Schnell JR, Chou JJ (2009) Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA 106(18):7379-7384.
25. Duque MD, et al. (2011) Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J Med Chem 54(8):2646-2657.
26. Zhao X, Li C, Zeng S, Hu W (2011) Discovery of highly potent agents against influenza A virus. Eur J Med Chem 46(1):52-57.
27. Wang C, Takeuchi K, Pinto LH, Lamb RA (1993) Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block. J Virol 67(9):5585-5594.
28. Sattler M, Schleucher J, Griesinger C, Smith ME, Eck ERHv (1999) Heteronuclear Multidimensional NMR Experiments for the Structure Determination of Proteins in Solution Employing Pulsed Field Gradients (Elsevier, Amsterdam).
29. Venters RA, Farmer BT, 2nd, Fierke CA, Spicer LD (1996) Characterizing the use of perdeuteration in NMR studies of large proteins: 13C, 15N and 1H assignments of human carbonic anhydrase II. J Mol Biol 264(5):1101-1116.
30. Cady SD, Wang J, Wu Y, DeGrado WF, Hong M (2011) Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J Am Chem Soc 133(12):4274-4284.
31. Cavanagh J, Fairbrother WJ, Palmer AG, Rance M, Skelton NJ (2007) Protein NMR Spectroscopy: Principles and Practice (Academic, Amsterdam, Boston).
32. Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM (2003) The Xplor-NIH NMR molecular structure determination package. J Magn Reson 160(1):65-73.
33. Schnell JR, Chou JJ (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451(7178):591-595.
34. Andreas LB, Eddy MT, Chou JJ, Griffin RG (2012) Magic-angle-spinning NMR of the drug resistant S31N M2 proton transporter from influenza A. J Am Chem Soc 134(17): 7215-7218.
35. Hu J, Fu R, Cross TA (2007) The chemical and dynamical influence of the anti-viral drug amantadine on theM2proton channel transmembrane domain. Biophys J 93(1):276-283.
36. Acharya R, et al. (2010) Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc Natl Acad Sci USA 107(34):15075-15080.
37. Carnevale V, Fiorin G, Levine BG, Degrado WF, Klein ML (2010) Multiple Proton Confinement in the M2 Channel from the Influenza A Virus. J Phys Chem C Nanomater Interfaces 114(48):20856-20863.
38. Paton NI, et al. (2011) Chloroquine for influenza prevention: A randomised, doubleblind, placebo controlled trial. Lancet Infect Dis 11(9):677-683.
39. Walsh ST, et al. (2003) The hydration of amides in helices; a comprehensive picture from molecular dynamics, IR, and NMR. Protein Sci 12(3):520-531.
40. Leiding T, Wang J, Martinsson J, DeGrado WF, Arsköld SP (2010) Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc Natl Acad Sci USA 107(35):15409-15414.
41. Sharma M, et al. (2010) Insight into the mechanism of the influenza A proton channel from a structure in a lipid bilayer. Science 330(6003):509-512.